Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Estimated Industry Valuation for the Thrombosis And Hemostasis Biomarkers Sector?
In recent times, there has been a significant growth in the size of the thrombosis and hemostasis biomarkers market. The market is predicted to expand from $4.8 billion in 2024 to about $5.17 billion in 2025, marking a compound annual growth rate (CAGR) of 7.8%. This expansion during the historic period can be linked to factors such as an upsurge in cardiovascular diseases, the aging global population, the rise in situations of cancer-related thrombosis, an increase in obesity and sedentary life patterns, along with a surge in diabetes and metabolic syndrome instances.
In the coming years, the thrombosis and hemostasis biomarkers market is projected to witness robust growth, reaching $6.87 billion in 2029, with a compound annual growth rate (CAGR) of 7.4%. This growth throughout the forecast period is linked to increased stroke and ischemic conditions, heightened awareness of venous thromboembolism, a rise in hemophilia and other bleeding disorders, an expanding population requiring surgeries, and a rise in health care spending. Key trends over forecast period include advancements in biomarker detection techniques, the creation of high-sensitivity tests for D-dimer and fibrinogen, the introduction of point-of-care diagnostic tools, the application of AI in biomarker analysis and predictions, and the increasing automation in laboratory diagnostics.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24724&type=smp
What Forces Are Driving The Growth Of The Thrombosis And Hemostasis Biomarkers Market?
The thirst for specific and precision treatments is forecasted to propel the growth of the thrombosis and hemostasis biomarkers market. The term “specific and precision treatments” refers to cutting-edge therapeutic strategies that closely target a patient’s disease’s molecular and genetic attributes with the objective of increasing effectiveness and mitigating adverse impacts. The increasing comprehension of genetic and molecular fluctuations in diseases is fueling the demand for these therapies. They provide more personalized treatments for patients, amplifying the efficiency and diminishing adverse reactions. It paves the way for designing more exact diagnostic tools that can identify unique biomarkers through its support for thrombosis and hemostasis biomarkers, leading to superior targeted therapy for clotting disorders, and upgraded patient consequences. For instance, Novotech, an Australian contract research organization, reported in March 2024 that 43% of the 217 oncology therapies that received approval from the FDA by the end of 2023, are perceived as precision oncology treatments, and 78 incorporated Deoxyribonucleic Acid (DNA) or Next Generation Sequencing (NGS)-detectable biomarkers. Consequently, the emerging demand for specific and precision treatments will catalyze the growth of the thrombosis and hemostasis biomarkers market.
How Is The Thrombosis And Hemostasis Biomarkers Industry Segmented Across Key Parameters?
The thrombosis and hemostasis biomarkers market covered in this report is segmented –
1) By Product: Reagents And Consumables, Analyzers
2) By Test Type: D-Dimer, Anti-Thrombin III, Plasminogen, Soluble Fibrin, Factor VIII, Post-Thrombin (PT), Activated Partial Thromboplastin Time (APTT) Test, Other Test Types
3) By Application: Cardiovascular Disorders, Neurological Disorders, Oncology, Pregnancy-Related Disorders, Orthopedic Procedures
4) By End User: Hospitals, Diagnostics Laboratories, Pharmaceutical Companies, Academic Institutions, Home Healthcare Settings
Subsegments:
1) By Reagents And Consumables: Coagulation Reagents, Control And Calibration Materials, Immunoassay Kits
2) By Analyzers: Fully Automated Coagulation Analyzers, Semi-Automated Coagulation Analyzers, Point-Of-Care Coagulation Devices
What Notable Trends Are Shaping The Direction Of The Thrombosis And Hemostasis Biomarkers Market?
Leading businesses in the thrombosis and hemostasis biomarkers market are honing in on novel developments such as automated VWF activity assays. These innovations strive to increase the precision and reliability of diagnostic tests for bleeding disorders. Automated VWF activity assays are lab-intensive tests that use techniques like immunoturbidimetry or chemiluminescence to measure the efficiency of the von Willebrand factor – a significant blood glycoprotein in hemostasis necessary for platelet adhesion and stabilization of factor VIII – at binding to platelet glycoprotein Ib. This assists in diagnosing and monitoring von Willebrand disease. Siemens Healthineers, a medical technology firm based in Germany, unveiled the INNOVANCE VWF Ac assay in October 2022, an entirely automated VWF activity assay constructed to improve the specificity of VWF activity measurement. The assay employs VWF:GPIbM technology to directly judge platelet binding activity, providing greater accuracy and sensitivity than before. VWF is a largely acknowledged biomarker linked with both thrombosis and bleeding, with its levels and activity influencing the probability of bleeding incidents and clot formation. The test assists in finding formerly difficult to trace VWF variants, thereby facilitating improved diagnosis and handling of VWD. Further, the assay satisfies the recent criteria set by the American Society of Hematology (ASH), International Society on Thrombosis and Hemostasis (ISTH), and National Hemophilia Foundation (NHF). This highlights its clinical significance and the progression it brings to diagnostic techniques.
Which Companies Currently Dominate The Competitive Landscape In The Thrombosis And Hemostasis Biomarkers Industry?
Major companies operating in the thrombosis and hemostasis biomarkers market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthineers AG, Becton, Dickinson and Company (BD), Mayo Clinic Laboratories, bioMérieux S.A., Beckman Coulter Inc., QuidelOrtho Corporation, Bio-Rad Laboratories Inc., Cincinnati Children’s Hospital Medical Center, ARUP Laboratories, HORIBA Ltd., Werfen S.A., Pathkind Diagnostics Pvt. Ltd., Diagnostica Stago, Agilus Diagnostics, Helena Laboratories Corporations, Cleveland Clinic Laboratories, Diazyme Laboratories Inc., Biomedica Diagnostics Inc., Atlas Medical GmbH
Get The Full Report Here:
Which Geographic Regions Are Driving Demand In The Thrombosis And Hemostasis Biomarkers Market?
North America was the largest region in the thrombosis and hemostasis biomarkers market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the thrombosis and hemostasis biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=24724&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model